•Q4 operating cash inflow was $1.4m up 481% on same quarter prior year
• Revenue of $1.43 million, an increase of 12% on the March 2017 quarter ($1.27m) and 367% ahead of the June 2016 quarter
• FY17 total operating cash inflow was $5.02m ($5.5m including R&D Rebate) and FY17 Operating revenue totalled $4.24m (excludes R&D Rebate), 210% higher than FY16
• Positive operational performance and growth across key metrics: o Over 830,000 users on the MedAdvisor platform, an increase of 17% on the March 2017 quarter o Expanded the MedAdvisor Pharmacy Network, to over 2,600+, with MedAdvisor now providing its platform to all of Discount Drug Stores (DDS) nationwide
• Dr David Chatterton (ex Aconex Ltd CTO – ASX:ACX) appointed Chief Technology Officer ahead of next phase of growth • New pharmacy software platform developed “PlusOne” that will provide additional pharmacy services and expand revenue opportunities for MedAdvisor and network pharmacy customers
- Forums
- ASX - By Stock
- MDR
- Ann: MDR Jun-17 Quarterly Report & 4C
Ann: MDR Jun-17 Quarterly Report & 4C, page-2
Featured News
Add MDR (ASX) to my watchlist
(20min delay)
|
|||||
Last
29.5¢ |
Change
-0.005(1.67%) |
Mkt cap ! $162.6M |
Open | High | Low | Value | Volume |
31.5¢ | 32.0¢ | 29.0¢ | $203.3K | 685.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 4908 | 29.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 100000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4908 | 0.290 |
2 | 31000 | 0.280 |
1 | 3636 | 0.275 |
2 | 23771 | 0.270 |
1 | 3500 | 0.265 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 100000 | 1 |
0.315 | 8755 | 2 |
0.320 | 10416 | 1 |
0.330 | 4000 | 1 |
0.335 | 62471 | 1 |
Last trade - 15.54pm 18/11/2024 (20 minute delay) ? |
Featured News
MDR (ASX) Chart |